PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial
Open Access
- 8 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
Introduction: PNPLA3, TM6SF2, and MBOAT7 genes play a crucial role in non-alcoholic fatty liver disease (NAFLD) development and worsening. However, few data are available on their treatment response influence. The aim of this trial is to explore the effect derived from silybin-phospholipids complex (303 mg of silybin-phospholipids complex, 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months) oral administration in NAFLD patients carrying PNPLA3-rs738409, TM6SF2-rs58542926, or MBOAT7-rs641738 genetic variants.Materials and Methods: In all, 92 biopsy-proven NAFLD patients were grouped in 30 NAFLD wild type controls, 30 wild type treated patients, and 32 mutated treated ones. We assessed glycemia (FPG), insulinemia, HOMA-IR, aspartate and alanine aminotransferases (AST, ALT), C-reactive protein (CRP), thiobarbituric acid reactive substance (TBARS), stiffness, controlled attenuation parameter (CAP), dietary daily intake, and physical activity at baseline and end of treatment.Results: The wild-type treated group showed a significant improvement of FPG, insulinemia, HOMA-IR, ALT, CRP, and TBARS (p < 0.05), whereas no improvements were recorded in the other two study groups. NAFLD wild type treated patients showed higher possibilities of useful therapeutic outcome (p < 0.01), obtained from the prescribed therapeutic regimen, independently from age, sex, comorbidities, medications, CAP, and stiffness in comparison to the mutated group.Discussion: The assessed mutations are independently associated with no response to a silybin-based therapeutic regimen and could be considered as useful predictive markers in this context.Clinical Trial Registry Number:www.ClinicalTrials.gov, identifier: NCT04640324.Keywords
This publication has 38 references indexed in Scilit:
- Hypovitaminosis D is Independently Associated with Metabolic Syndrome in Obese PatientsPLOS ONE, 2013
- Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitroJournal of Hepatology, 2012
- Determination of reliability criteria for liver stiffness evaluation by transient elastographyHepatology, 2012
- The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®Clinics and Research in Hepatology and Gastroenterology, 2012
- Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumptionThe American Journal of Clinical Nutrition, 2010
- Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver DiseaseGastroenterology, 2010
- A Common Variant in the Patatin-Like Phospholipase 3 Gene ( PNPLA3 ) Is Associated with Fatty Liver Disease in Obese Children and AdolescentsHepatology, 2010
- Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin ResistanceDiabetes, 2008
- A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations: Table 1Gut, 2006
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003